Balanced news tone
News Sentiment
XTLB sentiment intelligence
XTL Biopharmaceuticals Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
46
Balanced news tone
44 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+7.8% over one week, +36.6% over four weeks, trend inactive, and below fair value.
Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
7.8%
Price confirming higher
Trend fit
Trend inactive
36.6% over four weeks
Fair value
-47.3%
Below fair value
Market Dynamics buy signal
Value support
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
27
Negative
11
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J
This article provides a financial overview, specifically the enterprise value to EBITDA forward, for XTL Biopharmaceuticals Ltd. Sponsored ADR (LSX:A41X7J) on the Lang & Schwarz Exchange. It appears to be a stub or a data point from a financial platform like TradingView, indicati
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 05:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of XTL Biopharmaceuticals Ltd. – BOATS:XTLB
This article identifies the enterprise value to revenue forward for XTL Biopharmaceuticals Ltd., traded under the ticker BOATS:XTLB. It appears to be a stub or a section from a financial data platform, providing a title without further details or analysis within the visible conte
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 23:10
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of XTL Biopharmaceuticals Ltd. – BOATS:XTLB
This article provides the "Price to earnings forward" metric for XTL Biopharmaceuticals Ltd. (XTLB) listed on the Blue Ocean Alternative Trade System (BOATS) via TradingView. The page displays the current period value, change, and percentage change for this financial indicator, n
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 18:12
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of XTL Biopharmaceuticals Ltd. – TASE:XTLB
This article displays the "Enterprise value to EBIT forward" for XTL Biopharmaceuticals Ltd. (TASE:XTLB) on TradingView. It provides financial data and indicates that the market was closed with no trades executed for the company. The page is a financial overview on TradingView fo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 11:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of XTL Biopharmaceuticals Ltd. – TASE:XTLB
This article displays the "Price to sales forward" financial metric for XTL Biopharmaceuticals Ltd. (TASE:XTLB) directly from TradingView. It indicates that the company's market is currently closed with no trades recorded for this particular metric.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 04:10
- Source
- TradingView
Moomoo
Direct company coverage
XTL Completed The Acquisition Of Psyga Bio Ltd. >XTLB
XTL Biopharmaceuticals Ltd. has completed the acquisition of Psyga Bio Ltd. This action, following the execution of a definitive transaction agreement on June 13, 2026, marks the finalization of the deal. As a result, Psyga Bio is now a wholly-owned subsidiary of XTL.
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 20:41
- Source
- Moomoo
Stock Titan
Direct company coverage
XTL Biopharma (NASDAQ: XTLB) closes Psyga Bio deal and $1.5M raise
XTL Biopharma (NASDAQ: XTLB) has completed its acquisition of Psyga Bio Ltd., an Israeli biotechnology company focused on psychedelic and functional mushroom-derived therapeutics, making psychedelic operations its exclusive core business. XTL acquired approximately 83.40% of Psyg
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 08:09
- Source
- Stock Titan
The Manila Times
Direct company coverage
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Biopharmaceuticals (NASDAQ and TASE: XTLB) has completed the strategic acquisition of Psyga Bio Ltd., transforming XTL into a dedicated company in global psychedelic medicine. This acquisition expands XTL's intellectual property portfolio with clinical-stage biopharmaceutical
- Tone
- Positive 82/100
- Event
- Deals and strategy
- Published
- 01 Jul 2026 01:10
- Source
- The Manila Times
Quiver Quantitative
Direct company coverage
XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform
XTL Biopharmaceuticals has completed the acquisition of Psyga Bio, gaining 83.40% ownership and establishing itself in the psychedelic medicine field. The acquisition provides XTL with an advanced clinical pipeline focused on Psilocybin for mental health disorders, a GMP manufact
- Tone
- Positive 64/100
- Event
- Deals and strategy
- Published
- 30 Jun 2026 21:20
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
XTL buys Psyga Bio, taking control of 83.4% of shares
XTL Biopharmaceuticals (XTLB) has completed the acquisition of approximately 83.40% of Psyga Bio, transforming XTL into a psychedelic medicine company. This acquisition provides XTL with an advanced psilocybin-based clinical pipeline, a licensed GMP-ready manufacturing facility,
- Tone
- Positive 82/100
- Event
- Deals and strategy
- Published
- 30 Jun 2026 21:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
XTL Biopharmaceuticals (XTLB) holders pass all items at June 29 EGM
XTL Biopharmaceuticals (XTLB) shareholders approved all proposals at their Extraordinary General Meeting (EGM) held on June 29, 2026, in Tel Aviv. The meeting was originally scheduled for June 22, 2026, but was adjourned for a week due to a lack of quorum. The approved proposals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 20:40
- Source
- Stock Titan
Simply Wall Street
Direct company coverage
XTL Biopharmaceuticals (Nasdaq:XTLB) - Stock Analysis
This stock analysis provides an overview of XTL Biopharmaceuticals (Nasdaq:XTLB), a biopharmaceutical company focused on autoimmune diseases. It highlights the company's financial metrics, risk factors such as high volatility and low revenue, and recent corporate developments inc
- Tone
- Negative 33/100
- Event
- Earnings
- Published
- 24 Jun 2026 18:10
- Source
- Simply Wall Street
Stock Titan
Direct company coverage
XTL Biopharmaceuticals (XTLB) delays Extraordinary General Meeting after quorum shortfall
XTL Biopharmaceuticals (XTLB) has delayed its Extraordinary General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for June 22, 2026, has been adjourned for one week and is now set to reconvene on June 29, 2026, at 4:00 p.m. Israel time, at the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 04:41
- Source
- Stock Titan
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd
This article provides an overview of X T L Biopharmaceuticals Ltd (XTLB), focusing on its stock performance and the lack of publicly disclosed revenue breakdown data. It notes that the company's stock closed at $2.540, up 3.25%, with a market cap of $5.76 million. The detailed bu
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 07:09
- Source
- TradingKey
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd (XTLB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of X T L Biopharmaceuticals Ltd (XTLB) focusing on its dividend history and stock split events. It indicates that the company has distributed no dividends over the past five years and lists two future merger-related stock splits planned for March
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 19 Jun 2026 06:09
- Source
- TradingKey
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd (XTLB) Valuation: PE, PB & Fair Value Analysis
X T L Biopharmaceuticals Ltd (XTLB) has a current valuation score of 9.97, ranking 3rd in the Biotechnology & Medical Research industry. Its P/E ratio is -3.45, with other key valuation metrics like P/B, P/S, and P/CF not yet disclosed by the company. The stock closed at $2.540,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 04:09
- Source
- TradingKey
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd (XTLB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of X T L Biopharmaceuticals Ltd (XTLB), detailing its price momentum score of 6.65, current trading range between 2.07 and 2.70, and various technical indicators. It outlines specific buy and sell signals based on MACD, RSI, KDJ, and mov
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 09:39
- Source
- TradingKey
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd (XTLB) Institutional Confidence
The article details the institutional confidence score for X T L Biopharmaceuticals Ltd (XTLB), which currently stands at 3.00, unchanged from its previous score. It lists several key institutional shareholders and their shareholdings, noting a significant increase for Rabinovitc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 03:40
- Source
- TradingKey
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd (XTLB) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for X T L Biopharmaceuticals Ltd (XTLB), noting that no specific earnings forecast score is currently available for the company. It highlights that the average score for the Biotechnology & Medical Research industry is 8.13. The report a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 02:39
- Source
- TradingKey
TradingKey
Direct company coverage
X T L Biopharmaceuticals Ltd (XTLB) Financial Health: Profitability & Balance Sheet Analysis
X T L Biopharmaceuticals Ltd (XTLB) has a weak financial status with a current financial score of 4.49, ranking 385 out of 388 in the Biotechnology & Medical Research industry. Its operating efficiency is low, and relevant financial data for quality of earnings, operational effic
- Tone
- Negative 37/100
- Event
- Earnings
- Published
- 17 Jun 2026 02:10
- Source
- TradingKey
Město Břeclav
Direct company coverage
XTL Biopharmaceuticals (XTLB) Holds Steady Near Key Support in Tight Trading Range - Scalping Stock Signals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2026 07:00
- Source
- Město Břeclav
The Manila Times
Direct company coverage
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) announced it received a delist determination from Nasdaq for failing to file its Annual Report on Form 20-F for 2025. This adds to existing non-compliance issues with minimum stockholders’ equity and bid price requirements, for which the
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 23 May 2026 04:09
- Source
- The Manila Times
Investing.com UK
Direct company coverage
XTL Biopharmaceuticals faces additional Nasdaq delisting risk
XTL Biopharmaceuticals (NASDAQ:XTLB) has received an additional Nasdaq delisting notice for failing to file its 2025 Annual Report on Form 20-F. This adds to existing non-compliance issues regarding minimum stockholders' equity and bid price. The company's stock has significantly
- Tone
- Negative 13/100
- Event
- Market update
- Published
- 23 May 2026 00:08
- Source
- Investing.com UK
GuruFocus
Direct company coverage
XTL Biopharmaceuticals (XTLB) Faces Nasdaq Compliance Challenges Amid Stock Surge
XTL Biopharmaceuticals (XTLB) is facing Nasdaq compliance issues due to the absence of its annual report and failure to meet minimum stockholders' equity and bid price requirements. Despite these significant challenges, the stock saw a 5.98% increase in after-hours trading. The c
- Tone
- Negative 16/100
- Event
- Market update
- Published
- 22 May 2026 21:39
- Source
- GuruFocus
Moomoo
Direct company coverage
XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice
XTL Biopharmaceuticals has received a noncompliance notice from Nasdaq because its stock's minimum bid price fell below $1 for 30 consecutive business days. The company has 180 calendar days to regain compliance by ensuring its stock trades at $1 or more for at least 10 consecuti
- Tone
- Negative 20/100
- Event
- Market update
- Published
- 22 May 2026 21:08
- Source
- Moomoo
Stock Titan
Direct company coverage
Missed SEC filing puts XTL’s Nasdaq trading status at risk
XTL Biopharmaceuticals (Nasdaq:XTLB) has received another delist determination from Nasdaq for failing to file its 2025 Form 20-F annual report on time. This new non-compliance issue adds to existing deficiencies regarding minimum stockholders' equity and bid price, all of which
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 22 May 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nasdaq warns XTL Biopharmaceuticals (NASDAQ: XTLB) on late 20-F and listing defects
XTL Biopharmaceuticals (NASDAQ: XTLB) has received a delisting determination from Nasdaq due to its failure to file its Annual Report on Form 20-F for the year ended December 31, 2025. This new breach of Listing Rule 5250(c)(1) adds to existing deficiencies related to minimum sto
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 22 May 2026 20:39
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise
XTL Biopharmaceuticals has called an Extraordinary General Meeting for June 22, 2026, to seek shareholder approval for the acquisition of at least 80% of Psyga Bio Ltd., a conditional private placement of up to US$1.5 million, and a significant increase in authorized share capita
- Tone
- Negative 28/100
- Event
- Deals and strategy
- Published
- 19 May 2026 19:39
- Source
- The Globe and Mail
Investing.com
Direct company coverage
XTL Biopharmaceuticals schedules extraordinary shareholder meeting for June 22
XTL Biopharmaceuticals (NASDAQ: XTLB) has announced an Extraordinary General Meeting of Shareholders to be held on June 22, 2026, at 4:00 p.m. Israel time in Tel Aviv. The company released a Notice and Proxy Statement, along with a proxy card, to outline proposals and allow share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 13:11
- Source
- Investing.com